Stock data
Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc. (KYTX) reported net income of -US$161.31M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$169.83M | -US$161.31M | — |
| 2024 | — | — | -US$142.60M | -US$127.48M | — |
| 2023 | — | — | -US$62.41M | -US$60.37M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$38.32M | — |
| 2026-03-31 | — | -US$39.73M | — |
| 2025-12-31 | — | -US$37.80M | — |
| 2025-09-30 | — | -US$36.79M | — |
| 2025-06-30 | — | -US$42.08M | — |
| 2025-03-31 | — | -US$44.63M | — |
| 2024-12-31 | — | -US$37.49M | — |
| 2024-09-30 | — | -US$34.49M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.